Heparin-induced thrombocytopenia, paradoxical thromboembolism, and other adverse effects of heparin-type therapy

Hematology/Oncology Clinics of North America

Volumn 17, Issue 1, 2003, Pages 259-282

  Walenga, Jeanine M ^a   Frenkel, Eugene P ^b   Bick, Rodger L ^b,c,d  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c Dallas Thromb Hemostasis Clin Ctr   (United States)

^d ThromboCare Laboratories   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANCROD; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ARGATROBAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; CALCIUM; CLOPIDOGREL; DANAPAROID; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; FONDAPARINUX; HEPARIN; HIRUDIN; HIRULOG; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; THROMBIN INHIBITOR; TIROFIBAN; UROKINASE; WARFARIN;

ALOPECIA; AMNESIA; ANAPHYLAXIS; ANTIBODY TITER; ANTICOAGULANT THERAPY; BLEEDING; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; EOSINOPHILIA; EPIDURAL HEMATOMA; ERYTHEMA; FETUS MORTALITY; FEVER; HEART VALVE PROSTHESIS; HEMATOLOGICAL PARAMETERS; HIGH RISK PATIENT; HUMAN; HYPERKALEMIA; HYPOALDOSTERONISM; HYPOTENSION; LABORATORY TEST; LIVER TOXICITY; MULTICENTER STUDY; NAUSEA; OSTEOPOROSIS; PLASMAPHERESIS; PREGNANCY; PRIAPISM; PRIORITY JOURNAL; RESPIRATORY DISTRESS; REVIEW; SKIN NECROSIS; SKIN TOXICITY; SPINAL CORD HEMORRHAGE; TACHYCARDIA; TERATOGENICITY; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT OUTCOME; URTICARIA; WHEEZING;

ANTICOAGULANTS; EMBOLISM, PARADOXICAL; HEPARIN; HUMANS; THROMBOCYTOPENIA;

EID: 0037321324     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8588(02)00088-6     Document Type: Review

References (110)

1. Majerus PW, Broze Jr GJ, Miletich JP, et al. Anticoagulant, thrombolytic and antiplatelet drugs. In: Goodman Gilman A, Rall TW, Nies AS, et al, editors. The pharmacological basis of therapeutics. 8th edition. New York: Pergamon Press; 1990. p. 1311-31.
2. Messmore HL, Upadhyay G, Farid S, et al. Heparin-induced thrombocytopenia and thrombosis in cardiovascular surgery. In: Pifarré R, editor. New anticoagulants for the cardiovascular patient. Philadelphia: Hanley & Belfus Inc.; 1993. p. 83-94.
3. Walenga JM, Lewis BE, Hoppensteadt DA, et al. Management of heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndrome. Clin Appl Throm Hemost 1997;3(Suppl 1):S53-63.
4. Lewis BE, Walenga JM, Wallis DE. Anticoagulation with Novastan® (argatroban) in patients with heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndrome. Semin Thromb Hemost 1997;23(2):197-202.
5. Walenga JM, Bick RL. Heparin-induced thrombocytopenia, paradoxical thromboembolism, and other side effects of heparin therapy. Med Clin North Am 1998;82:635-58.
6. Warkentin TE, Kelton JG. Delayed onset of heparin-induced thrombocytopenia. Ann Intern Med 2001;135(7):502-6.
7. Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med 2001;344(17):1286-92.
8. Walenga JM, Jeske WP, Fasanella AR, et al. Laboratory diagnosis of heparin-induced thrombocytopenia. Clin Appl Thromb Hemost 1999;5(Suppl 1):S21-7.
9. Walenga JM, Jeske WP, Wood JJ, et al. Laboratory tests for heparin-induced thrombocytopenia: a multicenter study. Semin Hematol 1999;36(Suppl 1):22-8.
10. Bick RL. Heparin therapy and monitoring: guidelines and practice parameters for clinical and laboratory approaches. Clin Appl Thrombosis Hemostasis 1996;2(Suppl 1):S12-S20.
11. Hirsh J, Raschke R, Warkentin TE, et al. Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 1995;108:259S-75S.
12. Hirsh J, Warkentin TE, Shaughnessy SG, et al. Heparin and low-molecular-weight heparin, mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy and safety. Chest 2001; 119:64S-94S.
13. Warkentin TE, Hayward CP, Boshkov CK, et al. Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia. Blood 1994;84:3691-9.
14. Greinacher A, Eckhardt T, Mussman J, et al. Pregnancy complicated by heparin-associated thrombocytopenia: management by a prospective in vitro selected heparinoid (ORG 10172). Thromb Res 1993:71:123-6.
15. Stewart MW, Etches WS, Boshkov LK, et al. Heparin-induced thrombocytopenia: an improved method of detection based on lumi-aggregometry. Br J Haematol 1995;91:173-7.
16. Wallis DE, Workman DL, Lewis B, et al. Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia. Am J Med 1999;106(6):629-35.
17. Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med 1996;101:502-7.
18. Weismann RE, Tobin RW. Arterial embolism occurring during systemic heparin therapy. Arch Surg 1958;76:219-27.
19. Amiral J, Bridey F, Dreyfus M, et al. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb Haemost 1992;68(1): 95-6.
20. Aster RH. Heparin-induced thrombocytopenia and thrombosis. N Engl J Med 1995;332:1374-6.
21. Brandt JT, Isenhart CE, Osborne JM, et al. On the role of platelet Fcγ RIIA phenotype in heparin-induced thrombocytopenia. Thromb Haemost 1995;74:1564-72.
22. Cines DB, Tomaski A, Tannenbaum S. Immune endothelial cell injury in heparin-associated thrombocytopenia. N Engl J Med 1987;316:581-9.
23. Greinacher A, Michels I, Liebenhoff U, et al. Heparin-associated thrombocytopenia: immune complexes are attached to the platelet membrane by the negative charge of highly sulphated oligosaccharides. Br J Haematol 1993;84:711-6.
24. Chong BH, Ismail F, Cade J, et al. Heparin-induced thrombocytopenia: studies with a new low molecular weight heparinoid, Org 10172. Blood 1989;73(6):1592-6.
25. Kelton JG, Smith JW, Warkentin TE, et al. Immunoglobulin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4. Blood 1994; 83:3232-9.
26. Visentin GP, Ford SE, Scott JP, et al. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. J Clin Invest 1994;93:81-8.
27. Herbert JM, Savi P, Jeske WP, et al. Effect of SR121566A, a potent GPIIb/IIIa antagonist, on the HIT serum/heparin-induced platelet mediated activation of human endothelial cells. Thromb Haemost 1998;80:326-31.
28. Jeske WP, Walenga JM, Szatkowski E, et al. Effect of glycoprotein IIb/IIIa antagonists on the HIT serum-induced activation of platelets. Thromb Res 1997;88:271-81.
29. Walenga JM, Michal K, Hoppensteadt D, et al. Vascular damage correlates between heparin-induced thrombocytopenia and the antiphospholipid syndrome. Clin Appl Thromb Hemost 1999;5(Suppl 1):S76-84.
30. Newman PM, Chong BH. Heparin-induced thrombocytopenia: new evidence for the dynamic binding of purified anti-PF4-heparin antibodies to platelets and the resultant platelet activation. Blood 2000;96:182-7.
31. Hughes M, Hayward CPM, Warkentin TE, et al. Morphological analysis of microparticle generation in heparin-induced thrombocytopenia. Blood 2000;96:188-94.
32. Baugh MJ, Prechel M, Hoppensteadt D, et al. The role of CD40-ligand and anti-annexin V antibodies in the pathophysiology of the APS and HIT. Blood 2000;96(11):272a.
33. Blank M, Shoenfeld Y, Tavor S, et al. Anti-PF4/heparin antibodies from patients with heparin-induced thrombocytopenia provoke direct activation of microvascular endothelial cells. Int Immunol 2002;14(2):121-9.
34. Greinacher A, Feigl M, Mueller-Eckhardt C. Crossreactivity studies between sera of patients with heparin-associated thrombocytopenia and a new low-molecular-weight heparin, reviparin. Thromb Haemost 1994;72(4):644-5.
35. Ahmad S, Walenga JM, Jeske WP, et al. Functional heterogeneity of antiheparin-platelet factor 4 antibodies: implications in the pathogenesis of the HIT syndrome. Clin Appl Thromb Hemost 1999;5(Suppl 1):S32-7.
36. Ahmad S, Walenga JM, Jeske WP, et al. Lack of thrombocytopenic responses after low-molecular-weight heparin usage is due to the generation of non-functional anti-heparin-PF4 antibodies. Blood 1999;94(10):624a.
37. Mattioli AV, Bonetti L, Sternieri S, et al. Heparin-induced thrombocytopenia in patients treated with unfractionated heparin: prevalence of thrombosis in a 1 year follow-up. Italian Heart J 2000;1(1):39-42.
38. Amiral J, Pouplard C, Vissac AM, et al. Affinity purification of heparin-dependent antibodies to platelet factor 4 developed in heparin-induced thrombocytopenia: biological characteristics and effects on platelet activation. Br J Haematol 2000;109(2):336-41.
39. Pouplard CA, Amiral J, Vissac AM, et al. Affinity purification of different heparin-dependent antibodies to PF4 developed in HIT. Biological characteristics and effects on platelet activation. Blood 1999;94(10):16a.
40. Walenga JM, Bick RL. Heparin-induced thrombocytopenia, paradoxical thromboembolism, and other side effects of heparin therapy. Card Clinics: Annual Drug Therapy 1998;2: 123-39.
41. Ahmad S, Walenga JM, Jeske WP, et al. Molecular weight and charge dependence of heparin on the pathogenic responses of anti-heparin platelet factor 4 antibodies. Thromb Haemost 2001;(Suppl July):P2729.
42. Muir JM, Andrew M, Hirsh J, et al. Histomorphometric analysis of the effects of standard heparin on trabecular bone in vivo. Blood 1996;88:1314-20.
43. Robitaille D, Leclerc JR, Laberge R, et al. Cardiopulmonary bypass with a low-molecular-weight heparin fraction (enoxaparin) in a patient with a history of heparin-associated thrombocytopenia. J Thorac Cardiovasc Surg 1992;103(3):597-9.
44. Roussi JH, Houbouyan LL, Goguel AF. Use of low-molecular-weight heparin in heparin-induced thrombocytopenia with thrombotic complications. Lancet 1984;1(8387):1183.
45. Gouault-Heilmann M, Payen D, Contant G, et al. Thrombocytopenia related to synthetic heparin analogue therapy. Thromb Haemost 1985;54(2):557.
46. Leroy J, LeClerc MH, Delahousse B, et al. Treatment of heparin-associated thrombocytopenia and thrombosis with low-molecular-weight heparin (CY 216). Semin Thromb Hemost 1985; 11(3):326-9.
47. Kelton JG, Warkentin TE. Diagnosis of heparin-induced thrombocytopenia. Still a journey, not yet a destination [editorial]. Am J Clin Pathol 1995;104:611-3.
48. Hussey CV, Bernhard VN, McLean M, et al. Heparin-induced platelet aggregation: in vitro confirmation of thrombotic complications. Ann Clin Lab Sci 1979;9:487-93.
49. Ortel TL, Gocherman JP, Califf RM, et al. Parenteral anticoagulation with the heparinoid Lomoparan (ORG 10172) in patients with heparin-induced thrombocytopenia and thrombosis. Thromb Haemost 1992;67(3):292-6.
50. Greinacher A, Pötzsch B, Amiral J, et al. Heparin-associated thrombocytopenia: isolation of the antibody and characterization of a multi-molecular PF-4 heparin complex as the major antigen. Thromb Haemost 1994;71:247-51.
51. Carlsson LE, Santoso S, Baurichter G, et al. Heparin-induced thrombocytopenia: new insights into the impact of the FcγRIIa-R-H131 polymorphism. Blood 1998;92(5):1526-31.
52. Chamberlin JR, Lewis B, Leya F, et al. Successful treatment of heparin-associated thrombocytopenia and thrombosis using hirulog. Can J Cardiol 1995;11(6):511-4.
53. Lewis BE, Wallis DE, Berkowitz SD, et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 2001;103(14):1838-43.
54. Greinacher A, Volpel H, Janssens U, et al. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia. A prospective study. Circulation 1999;99:73-80.
55. Greinacher A, Janssens U, Berg G, et al. Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Circulation 1999; 100(6):587-93.
56. Lewis BE, Walenga JM. Argatroban in heparin-induced thrombocytopenia type II and acute coronary syndrome. Pathophysiology of Haemostasis and Thrombosis 2003, in press.
57. Eichler P, Friessen HJ, Lubenow N, et al. Antihirudin antibodies in patients with heparin-induced thrombocytopenia treated with lepirudin: incidence, effects on aPTT and clinical relevance. Blood 2000;96:2373-8.
58. Wallis DE, Quintos R, Whermacher W, et al. Safety of warfarin anticoagulation in patients with heparin-induced thrombocytopenia. Chest 1999;116:1333-8.
59. Nand S, Robinson J. Plasmapheresis in the management of heparin-associated thrombocytopenia with thrombosis. Am J Hematol 1988;28:204-6.
60. Raible M, Walenga JM, Lewis BE, et al. Plasmapheresis successfully removes heparin-platelet factor 4 antibodies from patients with heparin-induced thrombocytopenia. Blood 1995;86(10) (Suppl 1):906a.
61. Cohen JI, Cooper MR, Greenberg CS. Streptokinase therapy of pulmonary emboli with heparin-associated thrombocytopenia. Arch Intern Med 1985;135:1725-6.
62. Fiessinger JN, Aiach M, Roncato M, et al. Critical ischemia during heparin-induced thrombocytopenia. Treatment by intra-arterial streptokinase. Thromb Res 1984;33:235-8.
63. Rao RC, Lewis BE, Johnson SA. Thrombolytic experience for treatment of thrombosis in patients with postoperative heparin-induced thrombocytopenia. Blood 1995;86(10) (Suppl 1):551a.
64. Lewis BE, Leya FS, Wallis D, et al. Failure of ancrod in the treatment of heparin-induced arterial thrombosis. Can J Cardiol 1994;10(5):559-61.
65. Pötzsch B, Klovekorn WP. Use of heparin during cardiopulmonary bypass in patients with as history of heparin-induced thrombocytopenia. N Engl J Med 2000;343:515.
66. Kappa JR, Horn III MK, Fisher CA, Cottrel ED, Ellison N, Addonizio Jr VP. Efficacy of iloprost (ZK36374) versus aspirin in preventing heparin-induced platelet activation during cardiac operations. J Thorac Cardiovasc Surg 1987;94(3):405-13.
67. Kappa JR, Fisher CA, Todd B. Intraoperative management of patients with heparin-induced thrombocytopenia. Ann Thorac Surg 1990;49:714-23.
68. Chong BH, Burgess J, Ismail F. The clinical usefulness of the platelet aggregation test for the diagnosis of heparin-induced thrombocytopenia. Thromb Haemost 1993;69(4):344-50.
69. Haas S, Walenga JM, Jeske W, et al. Heparin-induced thrombocytopenia: Clinical considerations of alternative anticoagulation with various glycosaminoglycans and thrombin inhibitors. Clin Appl Thrombosis/Hemostasis 1999;5(Suppl 1):52-9.
70. Magnani HN. Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with orgaran (Org 10172). Thromb Haemost 1993;70(4):554-61.
71. Lewis BE, Rao RC, Robinson JA, et al. Early plasmapheresis reduces mortality in patients with heparin-induced thrombosis. Blood 1995;86(10):919a.
72. Walenga JM, Lewis BE, Jeske WP, et al. Combined thrombin and platelet inhibition treatment for HIT patients. Hämostaseologie 1999;19:128-33.
73. Hirsh J. Heparin. N Engl J Med 1991;324(22):1565-74.
74. Levine LE, Bernstein JE, Soltani K. Heparin-induced cutaneous necrosis unrelated to injection sites. Arch Dermatol 1983;119:400.
75. Morabia A. Heparin doses and major bleedings. Lancet 1986;1:1278.
76. Salzman EW, Deykin D, Shapiro RM, et al. Management of heparin therapy. N Engl J Med 1975;292:1046.
77. Thomas DP. Heparin prophylaxis and treatment of venous thromboembolism. Semin Hematol 1978;15:1.
78. Walker AM, Jick H. Prediction of bleeding during heparin therapy. JAMA 1980;244:1209.
79. Yett HS, Skillman JJ, Salzman EW. The hazards of aspirin plus heparin. N Engl J Med 1978;298:1092.
80. MedWatch - 2000, FDA. Lovenox: geriatric use. Food and Drug Administration, DHHS. May 30, 2000.
81. Warkentin TE, Soutar RL, Panju A. Acute systemic reactions to intravenous bolus heparin therapy: characterization and relationship to heparin-induced thrombocytopenia [abstract]. Blood 1992;80:160.
82. Jaffe MD, Willis PW. Multiple fractures associated with long-term sodium heparin therapy. JAMA 1965;193:152.
83. Levine M. Nonhemorrhagic complications of anticoagulant therapy. Semin Thromb Hemost 1986;12:63.
84. Howell R, Fidler J, Letsky E, et al. The risks of antenatal subcutaneous heparin prophylaxis: a controlled trial. Br J Obstet Gynecol 1983;90:1124.
85. Monreal M, Amiral J, Bridey F, et al. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb Haemost 1992;68: 95-8.
86. Barbour LA, Kick SD, Steiner JF, et al. A prospective study of heparin-induced osteoporosis in pregnancy using bone densitometry. Am J Obstet Gynecol 1994;170:862.
87. Dahlman TC. Osteoporotic fractures and the recurrence of thromboembolism during pregnancy and the puerperium in 184 women undergoing thromboprophylaxis with heparin. Am J Obstet Gynecol 1994;168:1265.
88. Hunt BJ, Doughty H, Majumdar G, et al. Thromboprophylaxis with low-molecular-weight heparin (Fragmin) in high-risk pregnancies. Thromb Haemost 1997;77:39-43.
89. Douketis J, Ginsberg JS, Burrows RF, et al. The effects of long-term heparin therapy during pregnancy on bone density. A prospective matched cohort study. Thromb Haemost 1996;75: 254-7.
90. Muir JM, Hirsh J, Weitz JI, et al. A histomorphometric comparison of the effects of heparin and low-molecular-weight heparin on cancellous bone in rats. Blood 1997;89:3236-42.
91. Panagakos FS, Jandinski JJ, Feder L, et al. Heparin fails to potentiate the effects of IL-1 betamediated bone resorption of fetal rat long bones in vitro. Biochimie 1995;77:915.
92. Shaughnessy SG, Young E, Deschamps P, et al. The effects of low-molecular-weight and standard heparin on calcium loss from fetal rat calvoria. Blood 1995;86:1368.
93. Murray WJ. Clinical presentations of heparin-induced thrombocytopenia. Semin Hematol 1998;35(Suppl):9.
94. Warkentin TE. Heparin-induced skin lesions. Br J Haematol 1996;92:494.
95. Hall JC, McConahay D, Gibson D, et al. Heparin necrosis an anticoagulation syndrome. JAMA 1980;244:1831.
96. Hill J, Caprini JA, Robbins JL. An unusual complication of minidose heparin therapy. Clin Orthop 1976;118:130.
97. Levine M, Hirsh J. Hemorrhagic complications of anticoagulant therapy. Semin Thromb Hemost 1986;12:39.
98. White PW, Sadd JR, Wensel RE. Thrombotic complications of heparin therapy. Ann Surg 1979; 190:595.
99. Bircher AJ, Itin PH, Buchner SA. Skin lesions, hypereosinophilia and subcutaneous heparin [letter]. N Engl J Med 1994;343:861.
100. Aull L, Chao H, Coy K. Hepafin-induced hyperkalemia. Ann Pharmacother 1990;24:244.
101. Lechy D, Gantt C, Linn V. Heparin-induced hypoaldosteronism. JAMA 1981;246:2189.
102. MedWatch - 2002, FDA. Lovenox: prosthetic valves, pregnancy, epidural bleeding. Food and Drug Administration. DHHS. January 9, 2002.
103. Chong BH. Heparin-induced thrombocytopenia. Br J Haematol 1995;89:431-9.
104. Walenga JM, Koza MJ, Lewis BE, Pifarré R. Relative heparin induced thrombocytopenic potential of low molecular weight heparins and new antithrombotic agents. Clin Appl Thrombosis/Hemostasis 1996;2(Suppl 1):S21-7.
105. Pouplard C, Lochmann S, Renard B, et al. Induction of monocyte tissue factor expression by antibodies to heparin-platelet factor 4 complexes developed in heparin-induced thrombocytopenia. Blood 2001;97(10):3300-2.
106. Jeske WP, Schlenker R, Bakhos M, et al. Are leukocytes important for platelet activation in heparin-induced thrombocytopenia? Ann Hematol 2000;79(Suppl 1):A46.
107. Jeske WP, Vasaiwala S, Schlenker R, et al. Leukocyte activation in heparin-induced thrombocytopenia. Blood 2000;96(11):29b.
108. Warkentin TE, Levine MN, Hirsch J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995; 332:1330-5.
109. Eichinger S, Kyrle PA, Brenner B, et al. Thrombocytopenia associated with low-molecular-weight heparin. Lancet 1991;337:1425-6.
110. Walenga JM, Ahmad S, Hoppensteadt D, Igbal O, Hursting MJ, Lewis BE. Argatroban therapy does not generate antibodies that alter its anticoagulant activity in patients with heparin-induced thrombocytopenia. Thromb Res 2002;105:401-5.